source
- Crossover fundraisings may hit $4.2 billion in 2026, with 2025 rounds still leading historic totalsCrossover rounds are viewed as a bridge to public markets, with Jim Healy of Sofinnova Investments saying a large raise signals a company has reached a level of maturity and broader institutional i…
- China biotech RiboX reports first human data for circular RNA therapiesChina biotech company RiboX has disclosed its initial human data on circular RNA therapeutics, marking the first clinical readout for this emerging platform. The study represents a milestone for t…